Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials.
Abstract | PURPOSE: PATIENTS AND METHODS: Combined efficacy outcomes with a longer follow-up in a phase Ib trial of REGONIVO and a phase II trial of LENPEM were examined in AGC with or without liver metastases (REGONIVO plus LENPEM cohort). We also investigated the efficacy of anti-PD-1 monotherapies (anti-PD-1 monotherapy cohort). A comparison of the immune microenvironment between gastric primary tumors and liver metastases was also conducted by multiplex IHC. RESULTS: In the REGONIVO plus LENPEM cohort, with a median follow-up of 14.0 months, objective response rate (ORR), median progression-free survival (mPFS), and median overall survival (mOS) were 46%, 7.8 months, and 15.6 months in patients with liver metastases, while 69%, 6.9 months, and 15.5 months in those without. In the anti-PD-1 monotherapy cohort, with a median follow-up of 27.6 months, ORR, mPFS, and mOS were 9%, 1.4 months, and 6.4 months in patients with liver metastases, while 22%, 2.3 months, and 9.0 months in those without. Multiplex IHC revealed liver metastases were associated with an abundance of immune-suppressive cells, such as tumor-associated macrophages and regulatory T cells, with fewer CD8+ T cells compared with gastric primary tumors. CONCLUSIONS:
|
Authors | Hiroki Yukami, Akihito Kawazoe, Yi-Tzu Lin, Shohei Koyama, Shota Fukuoka, Hiroki Hara, Naoki Takahashi, Takashi Kojima, Masako Asayama, Takako Yoshii, Hideaki Bando, Daisuke Kotani, Yoshiaki Nakamura, Yasutoshi Kuboki, Saori Mishima, Masashi Wakabayashi, Takeshi Kuwata, Masahiro Goto, Kazuhide Higuchi, Takayuki Yoshino, Toshihiko Doi, Hiroyoshi Nishikawa, Kohei Shitara |
Journal | Clinical cancer research : an official journal of the American Association for Cancer Research
(Clin Cancer Res)
Vol. 28
Issue 16
Pg. 3480-3488
(08 15 2022)
ISSN: 1557-3265 [Electronic] United States |
PMID | 35679062
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | ©2022 The Authors; Published by the American Association for Cancer Research. |
Chemical References |
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Clinical Trials as Topic
- Humans
- Immunotherapy
- Liver Neoplasms
(drug therapy, secondary)
- Nivolumab
(therapeutic use)
- Progression-Free Survival
- Stomach Neoplasms
(drug therapy, pathology)
- Treatment Outcome
- Tumor Microenvironment
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|